Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NanoBio has received its sixth US patent covering its new nanoemulsion technology. The patent encompasses composition of matter claims for the company’s lead anti-infective and vaccine product candidates.
Subscribe to our email newsletter
The newly issued patent (US 7,655,252) is licensed from the University of Michigan to NanoBio on an exclusive, worldwide basis. With the new patent, NanoBio now holds six US patents and has filed over 30 additional applications
The company said that the development of the nanoemulsion platform began in the 1990s at the University of Michigan, and has since been supported by over $110m in grants, investments and partnership funding.
James Baker, founder and CEO of NanoBio, said: “We are very pleased with this patent award in that the new claims circumscribe all of NanoBio’s anti-infective and dermatological products, as well as our intranasal and intramuscular vaccine adjuvants. The timing of this allowance coincides nicely with several very important development milestones at NanoBio.”
Reportedly, in December 2009, NanoBio and GlaxoSmithKline (GSK) entered into an exclusive licensing agreement in the US and Canada for the over-the-counter use of NB-001, NanoBio’s lead product for the treatment of herpes labialis (cold sores). The company is currently preparing to study the efficacy and safety of 0.3% NB-001 in two phase 3 trials.
In addition, NanoBio’s lead vaccine candidate, NB-1008, a seasonal influenza vaccine administered via a nasal dropper, has shown positive results in a recently completed phase 1 clinical study. The company is currently in partnership discussions with several parties regarding NB-1008.